Pub Date : 2024-09-16eCollection Date: 2024-07-01DOI: 10.18502/jovr.v19i3.13536
Hamid Reza Heidarzadeh, Akbar Derakhshan, Seyed Hossein Ghavami Shahri, Mohammad Reza Ansari Astaneh, Elham Bakhtiari, Saeed Shokouhi Rad, Mojtaba Abrishami
Purpose: To evaluate the effect of cataract surgery and visual impairment and the associated risk factors on the frequency of falls among older adults in northeast Iran.
Methods: This cross-sectional study, conducted between 2019 and 2020, analyzed the potential risk factors of falling in older adults over 50 years of age. To this end, 380 patients were randomly selected by convenience sampling and classified into two groups: those who had undergone cataract surgery in the last 12 months (surgery group) and those who had not (cataract group). The data were collected from the medical records and face-to-face interviews, and logistic regression was used to identify potential risk factors for falling.
Results: The frequency of falls in the cataract and surgery groups was 18.9% and 11.6%, respectively. The mean decimal visual acuity of the dominant eye was significantly lower in the cataract group than in the surgery group (P 0.001). There were no significant differences in the mean number of medications used, Charlson Comorbidity Index score, Instrumental Activities of Daily Living score, and 10-Meter Walk Test speed between the two groups. According to the results of backward logistic regression, taking more than four medications per day and slow gait speed were the most important factors influencing the frequency of falls in older adults.
Conclusion: Logistic regression analysis indicated that undergoing cataract surgery is not a significant protective factor against falls. However, older adults in the surgery group experienced fewer falls than in the other group. Besides, the results suggest that taking more than four medications daily and having a slow gait speed are significant fall risk factors.
{"title":"Visual and Demographic Risk Factors for Falls and the Impact of Cataract Surgery in Elderly Patients.","authors":"Hamid Reza Heidarzadeh, Akbar Derakhshan, Seyed Hossein Ghavami Shahri, Mohammad Reza Ansari Astaneh, Elham Bakhtiari, Saeed Shokouhi Rad, Mojtaba Abrishami","doi":"10.18502/jovr.v19i3.13536","DOIUrl":"10.18502/jovr.v19i3.13536","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the effect of cataract surgery and visual impairment and the associated risk factors on the frequency of falls among older adults in northeast Iran.</p><p><strong>Methods: </strong>This cross-sectional study, conducted between 2019 and 2020, analyzed the potential risk factors of falling in older adults over 50 years of age. To this end, 380 patients were randomly selected by convenience sampling and classified into two groups: those who had undergone cataract surgery in the last 12 months (surgery group) and those who had not (cataract group). The data were collected from the medical records and face-to-face interviews, and logistic regression was used to identify potential risk factors for falling.</p><p><strong>Results: </strong>The frequency of falls in the cataract and surgery groups was 18.9% and 11.6%, respectively. The mean decimal visual acuity of the dominant eye was significantly lower in the cataract group than in the surgery group (<i>P</i> <math><mo><</mo></math> 0.001). There were no significant differences in the mean number of medications used, Charlson Comorbidity Index score, Instrumental Activities of Daily Living score, and 10-Meter Walk Test speed between the two groups. According to the results of backward logistic regression, taking more than four medications per day and slow gait speed were the most important factors influencing the frequency of falls in older adults.</p><p><strong>Conclusion: </strong>Logistic regression analysis indicated that undergoing cataract surgery is not a significant protective factor against falls. However, older adults in the surgery group experienced fewer falls than in the other group. Besides, the results suggest that taking more than four medications daily and having a slow gait speed are significant fall risk factors.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"19 3","pages":"306-312"},"PeriodicalIF":1.6,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-16eCollection Date: 2024-07-01DOI: 10.18502/jovr.v19i3.9404
Dilru C Amarasekera, Vikram A Shankar, Reza Razeghinejad
Purpose: To discuss four cases of post-operative XEN gel stent luminal obstruction in patients with primary open angle glaucoma.
Case report: Four eyes in three patients with primary open angle glaucoma who received XEN stent implantation were found to have luminal obstruction of their stents. Stent obstruction can mimic filtering bleb failures not responding to bleb needling and antimetabolite injections. These obstructions were suspected to result from fibrin clots, iris pigment granules, or breakdown products of intraocular inflammation or hemorrhage. Treatment options trialed in these patients included bleb needling, 5-fluorouracil injection, and YAG laser to the proximal end of the XEN. Ultimately, all four eyes required XEN explantation and alternative filtering surgery.
Conclusion: XEN luminal obstruction is an important complication of stent placement that can ultimately lead to stent failure. Conservative measures such as laser or traditional bleb management may be considered before stent explantation or additional glaucoma surgery.
{"title":"XEN Gel Stent Failure Due to Luminal Obstruction.","authors":"Dilru C Amarasekera, Vikram A Shankar, Reza Razeghinejad","doi":"10.18502/jovr.v19i3.9404","DOIUrl":"10.18502/jovr.v19i3.9404","url":null,"abstract":"<p><strong>Purpose: </strong>To discuss four cases of post-operative XEN gel stent luminal obstruction in patients with primary open angle glaucoma.</p><p><strong>Case report: </strong>Four eyes in three patients with primary open angle glaucoma who received XEN stent implantation were found to have luminal obstruction of their stents. Stent obstruction can mimic filtering bleb failures not responding to bleb needling and antimetabolite injections. These obstructions were suspected to result from fibrin clots, iris pigment granules, or breakdown products of intraocular inflammation or hemorrhage. Treatment options trialed in these patients included bleb needling, 5-fluorouracil injection, and YAG laser to the proximal end of the XEN. Ultimately, all four eyes required XEN explantation and alternative filtering surgery.</p><p><strong>Conclusion: </strong>XEN luminal obstruction is an important complication of stent placement that can ultimately lead to stent failure. Conservative measures such as laser or traditional bleb management may be considered before stent explantation or additional glaucoma surgery.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"19 3","pages":"386-391"},"PeriodicalIF":1.6,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142368193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-16eCollection Date: 2024-07-01DOI: 10.18502/jovr.v19i3.13622
Hamid Riazi-Esfahani, Amin Ahmadi, Reza Sadeghi, Masoud Mirghorbani, Fariba Ghassemi, Mohammad Zarei, Hassan Khojasteh, Nikoo Bayan, Hooshang Faghihi, Elias Khalili Pour, Ahmad Mirshahi
Purpose: This study aimed to compare macular vascular changes one and three months after treatment with either panretinal photocoagulation (PRP) or intravitreal bevacizumab (IVB).
Methods: A total of 62 eyes with very severe non-proliferative diabetic retinopathy or early proliferative diabetic retinopathy without center-involved diabetic macular edema, were included in this retrospective study. Thirty-nine eyes were allocated to the PRP group, while 23 eyes were treated with IVB. Optical coherence tomography angiography (OCTA) was performed to measure foveal avascular zone (FAZ) characteristics as well as the densities of superficial and deep capillary plexuses (SCP and DCP).
Results: In the IVB group, the FAZ area and perimeter expanded at month one but returned to baseline level after three months. In the PRP group, however, the FAZ area and perimeter were rather steady. Changes in the FAZ area were significantly different between the treatment groups at month one (P = 0.02), but not at month three (P = 0.31). There was no significant difference in the change in FAZ circularity index between the two groups at each time point (P = 0.55 and P = 0.31). Similarly, changes in SCP density were not statistically significant between the two groups at both time points (all Ps 0.05). A comparison of the two treatment arms based on the mean change in DCP density revealed a significant difference at month one, but not at month three (P = 0.01 and P = 0.49, respectively).
Conclusion: Although bevacizumab and PRP have different short-term macular vascular responses, both therapies have the ability to normalize or stabilize vascular measures over time.
目的:本研究旨在比较使用全视网膜光凝(PRP)或玻璃体内贝伐单抗(IVB)治疗1个月和3个月后的黄斑血管变化:这项回顾性研究共纳入了62只患有非常严重的非增殖性糖尿病视网膜病变或早期增殖性糖尿病视网膜病变且无中心参与的糖尿病黄斑水肿的眼睛。39 只眼睛被分配到 PRP 组,23 只眼睛接受 IVB 治疗。研究人员进行了光学相干断层血管造影(OCTA),以测量眼窝血管缺损区(FAZ)的特征以及浅层和深层毛细血管丛(SCP和DCP)的密度:结果:在 IVB 组中,FAZ 的面积和周长在一个月时有所扩大,但在三个月后又恢复到基线水平。而在 PRP 组,FAZ 面积和周长相当稳定。治疗组之间的 FAZ 面积变化在第一个月有显著差异(P = 0.02),但在第三个月没有显著差异(P = 0.31)。两组在每个时间点的 FAZ 圆度指数变化没有明显差异(P = 0.55 和 P = 0.31)。同样,在两个时间点,SCP 密度的变化在两组之间也没有统计学意义(所有 Ps 均大于 0.05)。根据 DCP 密度的平均变化对两个治疗组进行比较后发现,在第一个月,两个治疗组之间存在显著差异,但在第三个月则不存在显著差异(分别为 P = 0.01 和 P = 0.49):结论:尽管贝伐单抗和PRP的短期黄斑血管反应不同,但这两种疗法都能使血管指标趋于正常或长期稳定。
{"title":"Evaluation of Foveal Vasculature by Optical Coherence Tomography Angiography after Pan-Retinal Photocoagulation versus Intravitreal Anti-VEGF Injections.","authors":"Hamid Riazi-Esfahani, Amin Ahmadi, Reza Sadeghi, Masoud Mirghorbani, Fariba Ghassemi, Mohammad Zarei, Hassan Khojasteh, Nikoo Bayan, Hooshang Faghihi, Elias Khalili Pour, Ahmad Mirshahi","doi":"10.18502/jovr.v19i3.13622","DOIUrl":"10.18502/jovr.v19i3.13622","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to compare macular vascular changes one and three months after treatment with either panretinal photocoagulation (PRP) or intravitreal bevacizumab (IVB).</p><p><strong>Methods: </strong>A total of 62 eyes with very severe non-proliferative diabetic retinopathy or early proliferative diabetic retinopathy without center-involved diabetic macular edema, were included in this retrospective study. Thirty-nine eyes were allocated to the PRP group, while 23 eyes were treated with IVB. Optical coherence tomography angiography (OCTA) was performed to measure foveal avascular zone (FAZ) characteristics as well as the densities of superficial and deep capillary plexuses (SCP and DCP).</p><p><strong>Results: </strong>In the IVB group, the FAZ area and perimeter expanded at month one but returned to baseline level after three months. In the PRP group, however, the FAZ area and perimeter were rather steady. Changes in the FAZ area were significantly different between the treatment groups at month one (<i>P</i> = 0.02), but not at month three (<i>P</i> = 0.31). There was no significant difference in the change in FAZ circularity index between the two groups at each time point (<i>P</i> = 0.55 and <i>P</i> = 0.31). Similarly, changes in SCP density were not statistically significant between the two groups at both time points (all <i>Ps</i> <math><mo>></mo></math> 0.05). A comparison of the two treatment arms based on the mean change in DCP density revealed a significant difference at month one, but not at month three (<i>P</i> = 0.01 and <i>P</i> = 0.49, respectively).</p><p><strong>Conclusion: </strong>Although bevacizumab and PRP have different short-term macular vascular responses, both therapies have the ability to normalize or stabilize vascular measures over time.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"19 3","pages":"313-323"},"PeriodicalIF":1.6,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-16eCollection Date: 2024-07-01DOI: 10.18502/jovr.v19i3.15047
Zahra Souri, Farzad Pakdel
Immune checkpoints (ICPs) are essential regulators of the immune system, ensuring a delicate balance between self-tolerance and autoimmune responses. ICP therapy is a rapidly growing cancer treatment strategy that inhibits the interaction between ICPs and their ligands. This biological interaction increases the ability of the immune system in combating cancer. However, in some cases, the use of these agents may lead to immune hyperactivity and, subsequently, autoimmune diseases. Graves' disease (GD), thyroid eye disease (TED), and orbital myopathy are complex autoimmune disorders characterized by the production of autoantibodies. The emergence of these treatment-related adverse events underscore the critical need for a deeper understanding of the immune-checkpoint axis in autoimmune diseases. In this review article, we provide a comprehensive survey of the biological mechanisms of ICPs that are most frequently targeted in cancer therapy, including CTLA-4, PD-1, PDL-1, and LAG3. Furthermore, we investigate the latest scientific findings on the adverse events associated with the inhibition of these ICPs. This paper will particularly focus on the potential risks these complications pose to ocular and orbital tissues, which are a concern in the context of cancer treatment.
{"title":"Immune Checkpoints and Graves' Disease, Thyroid Eye Disease, and Orbital Myopathy: A Comprehensive Review.","authors":"Zahra Souri, Farzad Pakdel","doi":"10.18502/jovr.v19i3.15047","DOIUrl":"10.18502/jovr.v19i3.15047","url":null,"abstract":"<p><p>Immune checkpoints (ICPs) are essential regulators of the immune system, ensuring a delicate balance between self-tolerance and autoimmune responses. ICP therapy is a rapidly growing cancer treatment strategy that inhibits the interaction between ICPs and their ligands. This biological interaction increases the ability of the immune system in combating cancer. However, in some cases, the use of these agents may lead to immune hyperactivity and, subsequently, autoimmune diseases. Graves' disease (GD), thyroid eye disease (TED), and orbital myopathy are complex autoimmune disorders characterized by the production of autoantibodies. The emergence of these treatment-related adverse events underscore the critical need for a deeper understanding of the immune-checkpoint axis in autoimmune diseases. In this review article, we provide a comprehensive survey of the biological mechanisms of ICPs that are most frequently targeted in cancer therapy, including CTLA-4, PD-1, PDL-1, and LAG3. Furthermore, we investigate the latest scientific findings on the adverse events associated with the inhibition of these ICPs. This paper will particularly focus on the potential risks these complications pose to ocular and orbital tissues, which are a concern in the context of cancer treatment.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"19 3","pages":"368-380"},"PeriodicalIF":1.6,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-16eCollection Date: 2024-07-01DOI: 10.18502/jovr.v19i3.10084
Hassan Lami, Sarrvesa Hari Vijay Singh, Svetlana Cherepanoff, J Males
Purpose: To present a rare case of metastatic conjunctival adenosquamous carcinoma (ASC) in the context of limited literature on the prognosis of ASC and suggested follow-up and surveillance.
Case report: We report a case of conjunctival ASC that metastasized to cervical lymph nodes five years after histological confirmation of complete local excision.
Conclusion: Long-term clinical follow-up and surveillance imaging are warranted to allow early detection of disease recurrence and/or metastasis.
{"title":"Late Metastasis in Conjunctival Adenosquamous Carcinoma.","authors":"Hassan Lami, Sarrvesa Hari Vijay Singh, Svetlana Cherepanoff, J Males","doi":"10.18502/jovr.v19i3.10084","DOIUrl":"10.18502/jovr.v19i3.10084","url":null,"abstract":"<p><strong>Purpose: </strong>To present a rare case of metastatic conjunctival adenosquamous carcinoma (ASC) in the context of limited literature on the prognosis of ASC and suggested follow-up and surveillance.</p><p><strong>Case report: </strong>We report a case of conjunctival ASC that metastasized to cervical lymph nodes five years after histological confirmation of complete local excision.</p><p><strong>Conclusion: </strong>Long-term clinical follow-up and surveillance imaging are warranted to allow early detection of disease recurrence and/or metastasis.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"19 3","pages":"381-385"},"PeriodicalIF":1.6,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose: To evaluate clinical presentation of chronic ocular graft-versus-host disease (GVHD), laterality of presentation, and longitudinal changes in patients undergoing allogeneic stem cell transplantation.
Methods: This is a retrospective longitudinal analysis of 60 eyes from 30 patients who had undergone hematopoietic stem cell transplantation. Demographic characteristics, clinical history, comorbidities, and other organ involvements were taken into account for analysis. We also undertook complete evaluation of the eyes, including cornea and anterior segment, posterior segment, Schirmer test, tear break-up time, ocular surface disease index, and intraocular pressure.
Results: The mean age of the patients was 34.3 11 years. The mean time for the diagnosis of ocular GVHD was 232.8 days (95% CI: 153.6, 311.9). The common findings at the first visit were bilateral blepharitis (n = 5, 17%), meibomitis (n = 4, 13%), and conjunctival congestion (n = 3, 10%). While bilateral cataract was present in one (3%) patient at the first visit, at 18 months, five (17%) patients had bilateral cataract and one (3%) patient had unilateral cataract. Grade 1 (n = 17), grade 2 (n = 9), and grade 3 (n = 4) superficial punctate epithelial erosions (SPEEs) were also observed at the first visit. However, SPEEs were seen in only 11 eyes at 18 months; all of these cases were grade 1 SPEEs. Long-term findings included cataract, telangiectasia, blepharospasm, conjunctival congestion, grade 1 SPEEs, corneal filaments, and tear film debris.
Conclusion: Although the initial presentations were SPEEs, meibomitis, blepharitis, and conjunctival congestion, these inflammatory conditions were reduced over time with proper management. However, there was an increase in the proportion of patients with cataract. It is important to regularly monitor these patients in order to identify and manage the initial as well as the late ocular manifestations of chronic GVHD.
{"title":"Clinical Manifestations and Outcomes of Ocular Graft Versus Host Disease following Allogeneic Stem Cell Transplantation.","authors":"Vijay Shetty, Priyanka Kashelkar, Sachin Punatar, Suhas Haldipurkar, Abhishek Hoshing, Rasika Thakur, Prachi Sankhe, Shabnam Tanwar, Tanvi Haldipurkar, Maninder Singh Setia, Anant Gokarn, Lingaraj Nayak, Avinash Bonda, Navin Khattry","doi":"10.18502/jovr.v19i3.13095","DOIUrl":"10.18502/jovr.v19i3.13095","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate clinical presentation of chronic ocular graft-versus-host disease (GVHD), laterality of presentation, and longitudinal changes in patients undergoing allogeneic stem cell transplantation.</p><p><strong>Methods: </strong>This is a retrospective longitudinal analysis of 60 eyes from 30 patients who had undergone hematopoietic stem cell transplantation. Demographic characteristics, clinical history, comorbidities, and other organ involvements were taken into account for analysis. We also undertook complete evaluation of the eyes, including cornea and anterior segment, posterior segment, Schirmer test, tear break-up time, ocular surface disease index, and intraocular pressure.</p><p><strong>Results: </strong>The mean age of the patients was 34.3 <math><mi>±</mi></math> 11 years. The mean time for the diagnosis of ocular GVHD was 232.8 days (95% CI: 153.6, 311.9). The common findings at the first visit were bilateral blepharitis (<i>n</i> = 5, 17%), meibomitis (<i>n</i> = 4, 13%), and conjunctival congestion (<i>n</i> = 3, 10%). While bilateral cataract was present in one (3%) patient at the first visit, at 18 months, five (17%) patients had bilateral cataract and one (3%) patient had unilateral cataract. Grade 1 (<i>n</i> = 17), grade 2 (<i>n</i> = 9), and grade 3 (<i>n</i> = 4) superficial punctate epithelial erosions (SPEEs) were also observed at the first visit. However, SPEEs were seen in only 11 eyes at 18 months; all of these cases were grade 1 SPEEs. Long-term findings included cataract, telangiectasia, blepharospasm, conjunctival congestion, grade 1 SPEEs, corneal filaments, and tear film debris.</p><p><strong>Conclusion: </strong>Although the initial presentations were SPEEs, meibomitis, blepharitis, and conjunctival congestion, these inflammatory conditions were reduced over time with proper management. However, there was an increase in the proportion of patients with cataract. It is important to regularly monitor these patients in order to identify and manage the initial as well as the late ocular manifestations of chronic GVHD.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"19 3","pages":"284-296"},"PeriodicalIF":1.6,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-16eCollection Date: 2024-07-01DOI: 10.18502/jovr.v19i3.13307
Saeed Rahmani, Farid Karimian, Kiana Hassanpour, Mohammad-Reza Jafarinasab, Sepehr Feizi, Sare Safi, Mohammad Ali Javadi
Purpose: To investigate the short-term results and performance of a modified Boston keratoprosthesis device manufactured by the Ophthalmic Research Center (ORC-KPro) in patients with end-stage corneal blindness.
Methods: This prospective interventional case series was conducted on patients with corneal blindness who were candidates for KPro. The inclusion criterion comprised patients with a best-corrected visual acuity (BCVA) of less than 20/200 in both eyes, in whom the main reason for vision loss was corneal pathology. The ORC-KPro was implanted using the method previously described for Boston KPro.
Results: This study focused on 12 eyes of 12 patients with an average age of 45.9 16.8 (range, 19 to 70) years. Eleven patients were male. The KPro indication was corneal blindness due to chemical burns in nine patients (75%) and failure of multiple previous corneal grafts in three patients (25%). Anatomical success was achieved in all patients. The preoperative BCVA was light perception (LP) in 10 eyes and hand motion in 1 eye. Except for one patient who was diagnosed with grade C proliferative vitreoretinopathy during the surgery, the vision of all other patients (91.6%) improved after surgery. The retroprosthetic membrane (RPM) was formed in two eyes (18.1%) after six months. Of the 12 patients, 10 (83.3%) were under treatment with two antiglaucoma medications before surgery. The intraocular pressure of three eyes (25%) was estimated to be high by tactile palpation; however, it decreased in two eyes to the acceptable range. One patient underwent retinal surgery due to total retinal detachment, and two patients (16.7%) underwent vitrectomy due to endophthalmitis.
Conclusion: The current study showed that, in the short term, the use of ORC-KPro achieved favorable anatomical success in patients with corneal blindness. However, the functional success rate was limited by the low visual potential due to advanced glaucoma in most patients.
{"title":"Clinical Outcomes of Stage 2 (Pivotal) Use of a Modified Keratoprosthesis Device (ORC-KPro) in Patients with End-stage Corneal Blindness.","authors":"Saeed Rahmani, Farid Karimian, Kiana Hassanpour, Mohammad-Reza Jafarinasab, Sepehr Feizi, Sare Safi, Mohammad Ali Javadi","doi":"10.18502/jovr.v19i3.13307","DOIUrl":"10.18502/jovr.v19i3.13307","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the short-term results and performance of a modified Boston keratoprosthesis device manufactured by the Ophthalmic Research Center (ORC-KPro) in patients with end-stage corneal blindness.</p><p><strong>Methods: </strong>This prospective interventional case series was conducted on patients with corneal blindness who were candidates for KPro. The inclusion criterion comprised patients with a best-corrected visual acuity (BCVA) of less than 20/200 in both eyes, in whom the main reason for vision loss was corneal pathology. The ORC-KPro was implanted using the method previously described for Boston KPro.</p><p><strong>Results: </strong>This study focused on 12 eyes of 12 patients with an average age of 45.9 <math><mo>±</mo></math> 16.8 (range, 19 to 70) years. Eleven patients were male. The KPro indication was corneal blindness due to chemical burns in nine patients (75%) and failure of multiple previous corneal grafts in three patients (25%). Anatomical success was achieved in all patients. The preoperative BCVA was light perception (LP) in 10 eyes and hand motion in 1 eye. Except for one patient who was diagnosed with grade C proliferative vitreoretinopathy during the surgery, the vision of all other patients (91.6%) improved after surgery. The retroprosthetic membrane (RPM) was formed in two eyes (18.1%) after six months. Of the 12 patients, 10 (83.3%) were under treatment with two antiglaucoma medications before surgery. The intraocular pressure of three eyes (25%) was estimated to be high by tactile palpation; however, it decreased in two eyes to the acceptable range. One patient underwent retinal surgery due to total retinal detachment, and two patients (16.7%) underwent vitrectomy due to endophthalmitis.</p><p><strong>Conclusion: </strong>The current study showed that, in the short term, the use of ORC-KPro achieved favorable anatomical success in patients with corneal blindness. However, the functional success rate was limited by the low visual potential due to advanced glaucoma in most patients.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"19 3","pages":"297-305"},"PeriodicalIF":1.6,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-16eCollection Date: 2024-07-01DOI: 10.18502/jovr.v19i3.13863
Aneesh Rahangdale, Elise Fernandez, Douglas S Weinberg, David Fleischman
Purpose: This study aimed to evaluate the effect of intraoperative positioning and ocular immobility on the amount of cerebrospinal fluid around the optic nerve in patients undergoing prone spinal surgery by measuring the optic nerve sheath diameter (ONSD) using ultrasound.
Methods: Consecutive participants (n = 15 patients, 30 eyes) were scanned preoperatively, intraoperatively approximately 20 minutes before the end of the surgery, and postoperatively in the post-anesthesia care unit at least 10 min after the completion of the surgery at one academic hospital.
Results: On average, patients who underwent prone spinal surgery had a 21% increase in ONSD intraoperatively, with a positive time-dependent relationship with the overall length of surgery (P 0.001). ONSDs postoperatively returned to baseline and were not significantly different from preoperative measurements.
Conclusion: Our findings suggest pooling and inadequate clearance of perioptic cerebrospinal fluid during prone spinal surgery that improves following termination of the procedure and return of the patient to an upright position.
{"title":"Investigating Optic Nerve Sheath Diameter in Prone Position Spinal Surgery Patients: A Pilot Study.","authors":"Aneesh Rahangdale, Elise Fernandez, Douglas S Weinberg, David Fleischman","doi":"10.18502/jovr.v19i3.13863","DOIUrl":"10.18502/jovr.v19i3.13863","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate the effect of intraoperative positioning and ocular immobility on the amount of cerebrospinal fluid around the optic nerve in patients undergoing prone spinal surgery by measuring the optic nerve sheath diameter (ONSD) using ultrasound.</p><p><strong>Methods: </strong>Consecutive participants (<i>n</i> = 15 patients, 30 eyes) were scanned preoperatively, intraoperatively approximately 20 minutes before the end of the surgery, and postoperatively in the post-anesthesia care unit at least 10 min after the completion of the surgery at one academic hospital.</p><p><strong>Results: </strong>On average, patients who underwent prone spinal surgery had a 21% increase in ONSD intraoperatively, with a positive time-dependent relationship with the overall length of surgery (<i>P</i> <math><mo><</mo></math> 0.001). ONSDs postoperatively returned to baseline and were not significantly different from preoperative measurements.</p><p><strong>Conclusion: </strong>Our findings suggest pooling and inadequate clearance of perioptic cerebrospinal fluid during prone spinal surgery that improves following termination of the procedure and return of the patient to an upright position.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"19 3","pages":"347-353"},"PeriodicalIF":1.6,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-16eCollection Date: 2024-07-01DOI: 10.18502/jovr.v19i3.15893
Hesam Hashemian, Tunde Peto, Renato Ambrósio, Imre Lengyel, Rahele Kafieh, Ahmed Muhammed Noori, Masoud Khorrami-Nejad
Artificial intelligence (AI) holds immense promise for transforming ophthalmic care through automated screening, precision diagnostics, and optimized treatment planning. This paper reviews recent advances and challenges in applying AI techniques such as machine learning and deep learning to major eye diseases. In diabetic retinopathy, AI algorithms analyze retinal images to accurately identify lesions, which helps clinicians in ophthalmology practice. Systems like IDx-DR (IDx Technologies Inc, USA) are FDA-approved for autonomous detection of referable diabetic retinopathy. For glaucoma, deep learning models assess optic nerve head morphology in fundus photographs to detect damage. In age-related macular degeneration, AI can quantify drusen and diagnose disease severity from both color fundus and optical coherence tomography images. AI has also been used in screening for retinopathy of prematurity, keratoconus, and dry eye disease. Beyond screening, AI can aid treatment decisions by forecasting disease progression and anti-VEGF response. However, potential limitations such as the quality and diversity of training data, lack of rigorous clinical validation, and challenges in regulatory approval and clinician trust must be addressed for the widespread adoption of AI. Two other significant hurdles include the integration of AI into existing clinical workflows and ensuring transparency in AI decision-making processes. With continued research to address these limitations, AI promises to enable earlier diagnosis, optimized resource allocation, personalized treatment, and improved patient outcomes. Besides, synergistic human-AI systems could set a new standard for evidence-based, precise ophthalmic care.
人工智能(AI)通过自动筛查、精确诊断和优化治疗计划,为改变眼科护理带来了巨大希望。本文回顾了将机器学习和深度学习等人工智能技术应用于主要眼科疾病的最新进展和挑战。在糖尿病视网膜病变方面,人工智能算法通过分析视网膜图像来准确识别病变,从而帮助临床医生开展眼科实践。IDx-DR(IDx Technologies Inc,美国)等系统已获得 FDA 批准,用于自主检测可转诊的糖尿病视网膜病变。对于青光眼,深度学习模型可评估眼底照片中的视神经头形态,以检测损伤情况。在老年性黄斑变性方面,人工智能可以从彩色眼底和光学相干断层扫描图像中量化色素沉着并诊断疾病的严重程度。人工智能还被用于筛查早产儿视网膜病变、角膜炎和干眼症。除筛查外,人工智能还能通过预测疾病进展和抗血管内皮生长因子反应来辅助治疗决策。然而,要广泛采用人工智能,必须解决潜在的局限性问题,如训练数据的质量和多样性、缺乏严格的临床验证以及监管审批和临床医生信任方面的挑战。另外两个重大障碍包括将人工智能整合到现有的临床工作流程中以及确保人工智能决策过程的透明度。通过持续研究解决这些限制因素,人工智能有望实现早期诊断、优化资源分配、个性化治疗和改善患者预后。此外,人类与人工智能系统的协同作用可为循证、精确的眼科护理设定新标准。
{"title":"Application of Artificial Intelligence in Ophthalmology: An Updated Comprehensive Review.","authors":"Hesam Hashemian, Tunde Peto, Renato Ambrósio, Imre Lengyel, Rahele Kafieh, Ahmed Muhammed Noori, Masoud Khorrami-Nejad","doi":"10.18502/jovr.v19i3.15893","DOIUrl":"10.18502/jovr.v19i3.15893","url":null,"abstract":"<p><p>Artificial intelligence (AI) holds immense promise for transforming ophthalmic care through automated screening, precision diagnostics, and optimized treatment planning. This paper reviews recent advances and challenges in applying AI techniques such as machine learning and deep learning to major eye diseases. In diabetic retinopathy, AI algorithms analyze retinal images to accurately identify lesions, which helps clinicians in ophthalmology practice. Systems like IDx-DR (IDx Technologies Inc, USA) are FDA-approved for autonomous detection of referable diabetic retinopathy. For glaucoma, deep learning models assess optic nerve head morphology in fundus photographs to detect damage. In age-related macular degeneration, AI can quantify drusen and diagnose disease severity from both color fundus and optical coherence tomography images. AI has also been used in screening for retinopathy of prematurity, keratoconus, and dry eye disease. Beyond screening, AI can aid treatment decisions by forecasting disease progression and anti-VEGF response. However, potential limitations such as the quality and diversity of training data, lack of rigorous clinical validation, and challenges in regulatory approval and clinician trust must be addressed for the widespread adoption of AI. Two other significant hurdles include the integration of AI into existing clinical workflows and ensuring transparency in AI decision-making processes. With continued research to address these limitations, AI promises to enable earlier diagnosis, optimized resource allocation, personalized treatment, and improved patient outcomes. Besides, synergistic human-AI systems could set a new standard for evidence-based, precise ophthalmic care.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"19 3","pages":"354-367"},"PeriodicalIF":1.6,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-16eCollection Date: 2024-07-01DOI: 10.18502/jovr.v19i3.13947
Mohammad Sharifi, Mohammad Yaser Kiarudi, Samaneh Gholamhoseinpour-Omran, Mohammad Alipour, Elham Bakhtiari
Purpose: To investigate the effect of intravenous tranexamic acid administered prior to external dacryocystorhinostomy (DCR) surgery to decrease intraoperative bleeding under general anesthesia.
Methods: This was a double-blinded randomized placebo-controlled trial. A total of 70 patients (35 intervention and 35 control) with nasolacrimal duct obstruction (NLDO) who were selected for DCR surgery between September 2021 and September 2022 were included. After clinical examinations and laboratory tests, patients were randomly classified into intervention and control groups. The intervention group received 10 mg/kg intravenous tranexamic acid to a maximum dose of 1 gr 30 minutes before the surgery. Controls received normal saline solution as a placebo. The amount of intraoperative bleeding and surgical time were compared between the two groups.
Results: The intervention group included 21 men (60%) and 14 women (40%), while the control group included 19 men (54.3%) and 16 women (45.7%). The mean ages of the participants were 55.46 10.8 years and 58.06 11.28 years in the intervention and control groups, respectively. A significant difference was observed between the two groups in the surgical time analysis (control group: 37.74 9.52 minutes vs intervention: 26.03 10.5 minutes; P 0.001). Additionally, there was a significant difference in the bleeding volume between the intervention (70.66 48.19 ml) and control (47.74 60 ml) groups (P 0.001).
Conclusion: Intravenous tranexamic acid administration before the DCR procedure can successfully control bleeding during the surgery.
{"title":"Intravenous Tranexamic Acid for Control of Bleeding during External Dacryocystorhinostomy under General Anesthesia: A Randomized Clinical Trial.","authors":"Mohammad Sharifi, Mohammad Yaser Kiarudi, Samaneh Gholamhoseinpour-Omran, Mohammad Alipour, Elham Bakhtiari","doi":"10.18502/jovr.v19i3.13947","DOIUrl":"10.18502/jovr.v19i3.13947","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the effect of intravenous tranexamic acid administered prior to external dacryocystorhinostomy (DCR) surgery to decrease intraoperative bleeding under general anesthesia.</p><p><strong>Methods: </strong>This was a double-blinded randomized placebo-controlled trial. A total of 70 patients (35 intervention and 35 control) with nasolacrimal duct obstruction (NLDO) who were selected for DCR surgery between September 2021 and September 2022 were included. After clinical examinations and laboratory tests, patients were randomly classified into intervention and control groups. The intervention group received 10 mg/kg intravenous tranexamic acid to a maximum dose of 1 gr 30 minutes before the surgery. Controls received normal saline solution as a placebo. The amount of intraoperative bleeding and surgical time were compared between the two groups.</p><p><strong>Results: </strong>The intervention group included 21 men (60%) and 14 women (40%), while the control group included 19 men (54.3%) and 16 women (45.7%). The mean ages of the participants were 55.46 <math><mo>±</mo></math> 10.8 years and 58.06 <math><mo>±</mo></math> 11.28 years in the intervention and control groups, respectively. A significant difference was observed between the two groups in the surgical time analysis (control group: 37.74 <math><mo>±</mo></math> 9.52 minutes vs intervention: 26.03 <math><mo>±</mo></math> 10.5 minutes; P <math><mo><</mo></math> 0.001). Additionally, there was a significant difference in the bleeding volume between the intervention (70.66 <math><mo>±</mo></math> 48.19 ml) and control (47.74 <math><mo>±</mo></math> 60 ml) groups (P <math><mo><</mo></math> 0.001).</p><p><strong>Conclusion: </strong>Intravenous tranexamic acid administration before the DCR procedure can successfully control bleeding during the surgery.</p>","PeriodicalId":16586,"journal":{"name":"Journal of Ophthalmic & Vision Research","volume":"19 3","pages":"340-346"},"PeriodicalIF":1.6,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443996/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}